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Abstract
Signal transduction through cAMP to activate gene expression via the cAMP-responsive element (CRE) is one of the most
intensively studied transcription pathways. In this pathway, transcription factor CRE-binding protein (CREB) recognizes the
CRE enhancer on DNA. The CREB protein is activated via phosphorylation at serine 133 by protein kinase A and then is
able to recruit coactivator CREB-binding protein (CBP) and its homologue p300. This recruitment of CBP/p300 is required
for transcription activation. The mechanism for CBP/p300 to participate in this transcription process is still unclear. CBP and
p300 are histone acetyltransferases (HAT) and able to associate with other HAT proteins. It has been reported that the
regulation of nuclear receptor-mediated transcription initiation by p300 requires chromatin and its HAT function. The data
shown here indicate that the requirements for chromatin and p300 HAT activity also apply to the activation of CREB-
mediated transcription. Serine 133-phosphorylated CREB recruits p300 onto chromatin for efficient acetylation of
nucleosomes. This targeted acetylation by p300 is essential to CREB-dependent transcription pathway. ß 2001 Elsevier
Science B.V. All rights reserved.
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1. Introduction
Adenoviral E1A-binding protein p300 and CREB-
binding protein CBP are highly conserved in their
primary sequences and are closely related in their
functions [1^5]. Many studies have suggested that
CBP/p300 is critically involved in control of develop-
ment, proliferation, di¡erentiation, and apoptosis
[6,7]. These physiological functions of CBP/p300 de-
pend on its ability to serve as a transcription coac-
tivator [1,8]. CBP and p300 have been found to par-
ticipate in many signal transduction pathways in-
volving a wide variety of transcription factors [6,9].
It has been proposed that CBP/p300 is essential and
integral for many fundamental biological events. Pre-
cisely how CBP/p300 activates transcription remains
uncertain, however.
CBP and p300 have been shown to interact with
the basal transcriptional factors TFIIB and TFIID,
as well as with the RNA polymerase II through
RNA helicase A [10^12]. These observations suggest
that one function of these coactivators is to serve as
transcriptional integrators or adaptors and stabilize
the pre-initiation complex. CBP and p300 have also
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been found to contain histone/protein acetyltransfer-
ase (HAT) activity [13,14]. They are able to interact
with other HAT proteins such as PCAF, Src-1 and
ACTR [15^17]. They can also acetylate other tran-
scription factors [18^21]. Further, p300 induced es-
trogen receptor-mediated transcription in vitro only
on the template with chromatin structure, but not
on the naked DNA [22]. This chromatin-dependent
transcription event required p300 HAT function
[23]. Therefore, through the activities of intrinsic
and associated HATs, CBP and p300 may activate
transcription through acetylating nucleosomal his-
tones and other transcription factors. It has been
shown that the recruitment of two yeast HAT com-
plexes, SAGA and NuA4, to chromatin by activa-
tors targeted factor-bound nucleosomes for acetyla-
tion [24]. This indicates that directing HAT by a
speci¢c activator to chromatin for acetylation may
cause activation of speci¢c genes. Thus, the recruit-
ment of the HAT proteins CBP and p300 by many
other activators and components of the basal tran-
scription machinery may not only allow them to
serve as adaptors, but also to direct them for acety-
lation of nucleosomes or other transcription factors.
The acetylation by CBP and p300 and/or their asso-
ciated HATs may cause remodeling of the chroma-
tin structure or modulate the transcription com-
plexes on the chromatin during activation of
transcription on speci¢c genes. It has been shown
that p300/CBP used both HAT-dependent and
HAT-independent mechanisms during transcription
coactivation [23].
One of the most intensively studied transcription-
al pathways is the signal transduction through
cAMP to activate genes via their enhancer (CRE)
[25]. This pathway consists of the transcription fac-
tor CREB, protein kinase A (PKA), and the coac-
tivator CBP or its homologue p300 [2,5,8,26]. There
is evidence suggesting that CBP/p300 may serve as
an adaptor between CREB and basal transcription
machinery to stabilize the pre-initiation complex
[27]. It has also been reported that CREB-mediated
gene expression required CBP HAT activity in vivo
[28]. It is still unclear how the HAT function of
CBP/p300 participates in this transcriptional pro-
cess. This work is a part of the e¡ort to understand
this question. An in vitro transcription system was
used containing a Gal4-CREB fusion protein to re-
cruit p300 onto a Gal4 site-containing transcription
template and HeLa nuclear extracts to provide the
basal transcription machinery. Chromatin structure
had been reconstituted on this transcription tem-
plate. In vitro transcription assays using this system
and in vivo transfection experiments using p300 mu-
tants revealed that acetylation of chromatin by p300
played a major role in CREB-mediated transcrip-
tion.
2. Materials and methods
2.1. Preparation of short chromatin
The short chromatin was prepared from HeLa
cells as described previously [29,30]. Brie£y, nuclei
isolated from HeLa cells were washed with BC600
(600 mM KCl in the BC bu¡er containing 20 mM
Tris^Cl, pH 7.9, 0.2 mM EDTA, 10 mM L-mercap-
toethanol, and 0.5 mM PMSF) and sonicated exten-
sively. The sonicated nuclear solution was fraction-
ated on a Sepharose CL-6B column in BC650
containing 0.34 M sucrose. The fractions were ana-
lyzed by electrophoresis both on 1.5% agarose gel for
visualizing stripped DNA and on 15% SDS^PAGE
for histones. The fractions that contain short chro-
matin bearing less than ¢ve nucleosomes were pooled
and dialyzed in BC0.
2.2. Chromatin reconstitution and analysis
Chromatin was reconstituted on pT3G5 plasmid
DNA as described [31]. A mixture of the plasmid
and the donor short chromatin prepared from
HeLa cells was equilibrated in BC1000. This mixture
was dialyzed from BC1000 to BC2000 containing 5 M
urea, and then slowly and gradually to BC600 with
urea in order to transfer histone octomers from the
donor short chromatin onto the plasmid. The mix-
ture was further dialyzed intensively in BC600 and
then in TE. The reconstituted chromatin plasmid
DNA (1.5 ml each) was puri¢ed by centrifugation
on a 20^50% sucrose gradient [30]. The puri¢ed chro-
matin plasmid DNA was analyzed by micrococcal
nuclease digestion (4 U/ml) at room temperature
for various times and separated on 1.5% TAE-aga-
rose gel [32].
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2.3. Protein expression constructs
Both Gal-CREB and its point mutant at serine 133
of the CREB portion (Gal-CREB M1) was generated
by fusing Gal4 amino acids (aa) 1^94 to the C-termi-
nus of the full-length CREB aa 1^341 and subcloning
the fusion gene into pET-23a vector (Novogen) be-
tween NdeI and EcoRI sites. After expression, the
fusion protein contains a 6Uhistidine tag at the C-
terminus. cDNA for PKAK catalytic subunit was
subcloned into pET 24a vector (Novogen) between
NdeI and BamHI sites.
For recombinant p300 (rp300) expression con-
struct, the full-length human p300 cDNA was fused
at the N-terminus with two copies of £ag tags and
subcloned into pFastBac vector (BRL Biotech) be-
tween BssHII and HindIII sites.
2.4. Protein expression and puri¢cation
Gal-CREB and PKA were expressed in Escherichia
coli BL21 DE3 strain (Novogen) as recommended by
the manufacturer. The bacterial cells were resus-
pended in BC100 (5 ml/g) and lysed by French Press.
The supernatant of the cell lysate was subject to am-
monium sulfate precipitation with 25^40% saturation.
The precipitate was resuspended in phosphate bu¡er
(pH 6.8) without salt and the conductivity of the so-
lution was adjusted to 780 WS (equivalent to 250 mM
KCl). Proteins were fractionated using a P11 column
(Whatman). After washing the column with the phos-
phate bu¡er containing 250 mM KCl (PS250), pro-
teins were eluted in a gradient of PS250^1500. The
fractions with conductivity of 1.2^2.2 mS, containing
the Gal-CREB protein, were pooled. The fractions
with lower conductivity, containing PKA, were also
pooled. Both Gal-CREB and PKA were further pu-
ri¢ed using Ni2-nitriloacetic acid (NTA)-agarose
a⁄nity chromatography (Qiagen) following the man-
ufacturer’s instructions. Gal-CREB was phosphory-
lated by PKA through co-expression with PKA in
bacteria. Alternatively, the puri¢ed Gal-CREB pro-
tein might also be phosphorylated in vitro by puri¢ed
PKA (500:2, w/w) at 30‡C for 20 min in 50 mM
MOPS (pH 6.8), 50 mM KCl, 2 mM MgCl2, 1 mM
DTT and 100 WM ATP. The serine 133 mutant Gal-
CREB M1 was also co-expressed with PKA in bac-
teria, and puri¢ed in the same way as Gal-CREB.
The £ag-tagged p300 protein (rp300) was ex-
pressed with the baculovirus expression system
(BRL Biotech) in Sf9 cells following the manufactur-
er’s instructions. The cells were washed in phosphate
bu¡ered saline and lysed in BC100/0.5% NP-40. The
supernatant of the cell lysate was ¢rst separated on a
P11 column. After elution in a gradient of BC100^
1000, the rp300-containing fractions were pooled and
incubated with M2-agarose (Kodak, 1%, v/v) at 4‡C
for 4 h. The beads were washed in BC300/0.1% NP-
40, ¢ve times, 15 ml each. The rp300 protein was
eluted at 4‡C for 1 h with rotating in BC100/0.1%
NP-40 containing 0.2 mg/ml £ag peptide (1:1, v/v).
2.5. Electrophoresis mobility shift assay
The 420 bp AvaI fragment of pG5 208-10 plasmid
[33], containing ¢ve copies of Gal4 sites and one copy
of nucleosome positioning sequence of 5S rRNA
gene, was labeled with 32P by Klenow. Dinucleo-
somes were assembled on the labeled DNA fragment
using the octomer transfer method with HeLa short
chromatin as donor, and further puri¢ed by centrifu-
gation on a 5^20% sucrose gradient [34]. The binding
reaction (30 Wl) contained 10 mM Tris^Cl (pH 7.5),
50 mM NaCl, 1 mM EDTA, 1 mM DTT, 5% glyc-
erol, 1 Wg poly(dI-dC), the labeled dinucleosome
probe (105 cpm), and either Gal-CREB M1 (50 ng),
P-Gal-CREB (50 ng), or rp300 (200 ng). After incu-
bation at room temperature for 30 min, the reaction
was separated on 4% polyacrylamide gel in 0.5%
TBE. The gel was dried before autoradiography.
2.6. HAT assay
Cold dinucleosomes containing Gal4-binding sites
were prepared as described above. The dinucleo-
somes (150 ng) were incubated at 30‡C for 10 min
with either P-Gal-CREB or Gal-CREB M1 (50 ng)
in 20 mM Tris^Cl (pH 7.9), 10 mM sodium butyrate,
1 mM EDTA, 1 mM DTT, 1 mM PMSF, and 10%
glycerol [30]. Then, rp300 (200 ng) was added and
the mixture was incubated for 10 more minutes. The
acetylation reaction was initiated by adding 14C-ace-
tyl-CoA (NEN, 8 nCi) [13,35]. After incubation at
30‡C for 30 min, the reaction was stopped by adding
protein-loading bu¡er and analyzed on a 15% SDS^
polyacrylamide gel.
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2.7. In vitro transcription assay
Assays were carried out as described previously
[24,36,37] except using HeLa nuclear extracts instead
of the puri¢ed basal transcription factors. Transcrip-
tion reaction (25 Wl) contained BC100 bu¡er, 3 mM
MgCl2, 150 U RNase T1, 0.5 mM ATP, 0.5 mM
CTP, 25 WM UTP, 100 WM 3P-O-methyl GTP (Phar-
macia), 1 Wl [K-32P]UTP (NEN, 3000 Ci/mmol, 10
mCi/ml), HeLa nuclear extracts (50 Wg), DNA tem-
plates, and either P-Gal-CREB (100 ng) or rp300
(400 ng). pT3G5 plasmid, either naked DNA (100
ng) or reconstituted chromatin (1 Wg), was used as
a transcription template. A core promoter template
(pMLv53, 40 ng) was also included in the reaction as
control [38]. As indicated, acetyl coenzyme A (acetyl-
CoA) (1 WM) or deacetylase inhibitor trichostatin A
(TSA, 5 WM) may be added ¢rst with the templates.
After incubation at 30‡C for 60 min, the reaction was
stopped by adding 200 Wl stop solution (20 mM Tris^
Cl, pH 8.0, 1 mM EDTA, 100 mM NaCl, and 1%
SDS) and 1 Wg tRNA as carrier. After extraction
with phenol/chloroform (1:1), RNA was precipitated
with ethanol, and analyzed on a 5% polyacrylamide
gel containing 8 M urea. After electrophoresis, the
gel was soaked in dH2O, dried, and subjected to
autoradiography.
2.8. Transfection and CAT assay
HeLa cells at 50% con£uence in 10 cm plates were
transfected with Lipofectamine (16 Wl, BRL) as de-
scribed by the manufacturer. One or 2 days after
transfection, the cells were lysed in 100 Wl bu¡er
followed by CAT assay using the organic phase ex-
traction procedure [8]. CAT activity was normalized
against co-transfected L-gal activity [39].
3. Results
Based on transcription modulation mechanism, an
in vitro transcription template (pG5HMC2AT) con-
taining ¢ve copies of heterologous Gal4-binding sites
at the upstream [38,40] was modi¢ed and used in this
study (Fig. 1A). The CREB-p300 transcription sys-
tem was recruited to this modi¢ed template (pT3G5)
through a fusion protein Gal-CREB. Because prox-
imal Sp1 sites exist usually at the promoters of the
native genes in cooperation with the upstream CRE
enhancers to activate transcription, Sp1 sites were
inserted into the transcription template upstream
and proximal to the TATA sequence. The Gal4 sites
in the template were £anked at each side by ¢ve
copies of the nucleosome positioning sequences
from the 5S rRNA gene of sea urchin [33] in order
to help assembly of nucleosomes on the plasmid.
After chromatin reconstitution by the octomer trans-
fer method using short chromatin prepared from
HeLa cells, the chromatin template DNA pT3G5
was puri¢ed on a sucrose gradient (Fig. 1B). The
Fig. 1. Reconstitution of chromatin on transcription template.
(A) Diagram of the transcription unit of the template plasmid
pT3G5. UAS contains ¢ve copies of Gal4-binding sites. (B) The
reconstituted chromatin was puri¢ed on sucrose gradient. The
fractions eluted from the gradient were treated to strip DNA
and analyzed on 1% agarose gel. The gel was stained with
ethidium bromide. (C) The puri¢ed chromatin template was an-
alyzed by micrococcal nuclease digestion followed by electro-
phoresis on an agarose gel. Numbers on the top represent di-
gestion time in minutes. Dashes on the right indicate visible
nucleosome arrays.
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dense fractions containing pT3G5 chromatin were
pooled and analyzed by digestion with micrococcal
nuclease (Fig. 1C). The results of the micrococcal
nuclease digestion indicate that nucleosomes were
assembled on the template plasmid pT3G5 success-
fully.
The transcription system used in this study re-
quires the fusion protein Gal-CREB that has been
phosphorylated at serine 133 of the CREB portion
by PKA. In the preparation of the phosphorylated
Gal-CREB protein, Gal-CREB and PKA catalytic
subunit were co-expressed in bacteria. The phospho-
serine 133-speci¢c antibody recognized the Gal-
CREB puri¢ed from the co-expression bacteria (P-
Gal-CREB) but not the Gal-CREB without co-ex-
pression with PKA nor the co-expressed Gal-CREB
bearing a point mutation at serine 133 (Gal-CREB
M1) (Fig. 2A, right). These results indicate that PKA
phosphorylated Gal-CREB at serine 133 in bacteria
as expected. Both puri¢ed P-Gal-CREB and Gal-
CREB M1, that were co-expressed with PKA, mi-
grated faster during electrophoresis than unphos-
phorylated Gal-CREB (Fig. 2A, left), suggesting
that PKA might also phosphorylate CREB in bacte-
ria at residues other than serine 133.
To test whether the reconstituted chromatin tem-
plate recruited the P-Gal-CREB and then p300 pro-
teins normally, a 32P-labeled dinucleosome probe
bearing ¢ve copies of Gal4 sites and puri¢ed Gal-
CREB and p300 proteins (Fig. 2A,B) were used in
electrophoresis mobility shift assays. As shown in
Fig. 3A, both P-Gal-CREB and its point mutant
Fig. 2. Preparation of Gal-CREB and rp300 proteins. (A) Gal-
CREB was expressed in E. coli, puri¢ed by P11 and Ni-NTA
a⁄nity chromatography, and separated on 10% SDS^PAGE.
Phosphorylated Gal-CREB (P-Gal-CREB) was phosphorylated
by co-expression with PKA in bacteria. Proteins were analyzed
by Coomassie staining (left) and by Western blot with anti-
phosphoserine 133 antibody (Upstate Biotechnology) (right).
(B) Recombinant full-length p300 (rp300) was expressed in Sf9
cells and puri¢ed by P11 and M2-agarose immunochromatogra-
phy. Whole cell lysate and puri¢ed rp300 were analyzed by 6%
SDS^PAGE and followed by Coomassie staining.
Fig. 3. Recruiting p300 by P-Gal-CREB to nucleosomes for ef-
¢cient acetylation. (A) 32P-Labeled and Gal4 site-containing di-
nucleosomes were incubated with either P-Gal-CREB or Gal-
CREB M1, and then with rp300 as indicated. The binding reac-
tions were analyzed on 4% polyacrylamide gel. Autoradiograph
is shown. (B) After incubation of the cold dinucleosomes se-
quentially with Gal-CREB and rp300, HAT assay was followed
with 14C-acetyl-CoA. The labeled core histones were denatured
and separated by 15% SDS^PAGE. Fluorograph is shown. The
HAT reaction for each lane contained free core histones as sub-
strates. P-KID, peptides derived from the kinase-inducible do-
main of CREB that are phosphorylated at serine 133; £ag, the
£ag peptide.
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Gal-CREB M1 bound to the dinucleosome probe.
The p300 protein was recruited onto the Gal-
CREB/dinucleosome complex only when the Gal-
CREB had been phosphorylated, but not when the
Gal-CREB M1 mutant protein was used. Thus, the
recruitment of p300 onto the P-Gal-CREB/dinucleo-
some complex appears speci¢c to the interaction be-
tween the KID domain of CREB containing phos-
phoserine 133 (P-KID) and the CREB-binding
domain of p300. This result was con¢rmed using P-
KID peptides, which blocked the formation of the
p300/Gal-CREB/dinucleosome supercomplex.
Further experiments were carried out using the
same dinucleosome probe but without 32P labeling
in order to see whether the recruitment of p300 by
P-Gal-CREB to nucleosomal DNA was required for
acetylation of nucleosomes. In these experiments, the
Gal-CREB and p300 proteins were allowed to form
complexes on the dinucleosomes ¢rst, and HAT as-
say was followed using 14C-acetyl-CoA. Although
free p300 could acetylate nucleosomes, the presence
of P-Gal-CREB allowed p300 to acetylate nucleo-
somes more e⁄ciently (Fig. 3B). P-KID peptides,
but not irrelevant peptides (£ag), repressed the ace-
tylation in the presence of P-Gal-CREB, suggesting
that the recruitment of p300 to the activator-bound
nucleosomal DNA enhances acetylation of nucleo-
somes, i.e. previously described the HAT protein-tar-
geted acetylation.
To answer the question of how acetylation of
chromatin by p300 is involved in CREB-mediated
transcription, in vitro transcription assays were per-
formed using the template DNA pT3G5, both naked
and assembled with nucleosomes. On the naked tem-
plate, transcription occurred easily in the presence of
the activator P-Gal-CREB (Fig. 4A). In contrast,
transcription was severely repressed on the chroma-
tin template (Fig. 4B). Similar to the previous report
using the estrogen receptor transcription system [22],
induction of the Gal-CREB-mediated transcription
by p300 was observed only on the chromatin tem-
plate but not on the naked template. There was no
di¡erence in transcription level on the naked tem-
plate when P-Gal-CREB was used either with, or
without, the addition of p300 (Fig. 4A). On the other
hand, the transcription on the chromatin template
was enhanced by the additional p300 (Fig. 4B,C).
To test whether the enhancement of transcription
on the chromatin template by p300 was induced by
acetylation, acetyl-CoA and the deacetylase inhibitor
TSA were added into transcription reactions. Both
acetyl-CoA and TSA augmented transcription on
chromatin but not on naked templates (Fig. 4A^C).
Acetyl-CoA may augment transcription on chroma-
Fig. 4. Derepression of CREB-mediated transcription on chro-
matin by p300 through acetylation. In vitro transcription assays
were carried out on either naked (A) or chromatin (B,C) tem-
plate (pT3G5) with rp300 and P-Gal-CREB in HeLa nuclear
extracts either in the presence or absence of acetyl-CoA or
TSA. Acetyl-CoA was added in all reactions in panel C. Major
late core promoter (MLP) template (pMLv53) was included as
control in all reactions.
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tin through directly accelerating the rate of acetyla-
tion, while TSA may a¡ect the level of acetylation by
inhibiting deacetylase activities in nuclear extracts.
Each reaction contained endogenous p300 provided
from nuclear extracts. The improvement of CREB-
mediated transcription by acetyl-CoA and TSA was
observed only in the presence of P-Gal-CREB, how-
ever (Fig. 4B,C), indicating that the recruitment of
p300 is required for the acetylation on chromatin.
Thus, these data combined with those presented in
Fig. 3 suggest that the p300 recruited onto the acti-
vator-bound chromatin template targets for e⁄cient
acetylation of nucleosomes at the promoter, there-
fore resulting in derepression of transcription.
We further investigated this p300-dependent tran-
scription event in vivo using two p300 mutant ex-
pression constructs, p300 HAT3 and p300 1-1737.
The p300 HAT3 mutant was made the same as
p300mutAT2 reported previously, that lacked HAT
activity [23]. The p300 1-1737 construct contains all
the sequences required for HAT function but lacks
CH3 and other C-terminal regions that are respon-
sible for binding to TBP, TFIIB and other coactiva-
tors. A CRE-containing reporter and expression vec-
tors for CREB and PKA catalytic subunit were co-
transfected into HeLa cells with the expression con-
structs for wild type and mutant p300 constructs.
The p300 proteins expressed from the transfected
constructs were recovered by immunoprecipitation
with anti-£ag antibodies. The wild type and mutant
p300 proteins were expressed at similar levels under
di¡erent conditions (Fig. 5). The level of CREB in
the cell was not a¡ected by expression of either PKA
or the recombinant p300 proteins. Transactivation of
the CRE reporter was induced by the expression of
PKA. Both the p300 HAT3 and 1-1737 mutants
repressed transactivation of the CRE reporter, con-
¢rming that both HAT-dependent and HAT-inde-
pendent transcriptions are involved in CREB-medi-
ated gene expression. The p300 HAT3 mutant
repressed the transactivation by more than 4-fold
compared to the wild type while the p300 1-1737
mutant did it by less than 1-fold. These results fur-
ther suggest that p300 HAT function plays a major
role in CREB-dependent transcription.
4. Discussion
CBP was found, originally, to participate in
cAMP-regulated transactivation of the CRE en-
hancer [25]. Later, its homologue, adenoviral E1A-
binding protein p300, was also shown to be able to
play a part in this transcription event [5]. In p300
knockout mice transactivation of the somatostatin
CRE reporter was not a¡ected, suggesting p300 itself
may not be essential for this transcription pathway
[41]. It is possible that both p300 and CBP can alter-
natively participate in the CREB-mediated transcrip-
tion. This study provides further evidence that p300
can serve as a coactivator in the CREB-mediated
transcription. In contrast, certain p300 functions in
nuclear receptor-dependent biological events, such as
activation of gene expression, upregulation of the cell
cycle inhibitor p21, and induction of F9 cell di¡er-
entiation, cannot be substituted by CBP [41,42]. One
Fig. 5. Activation of CREB-mediated transcription by p300 in
vivo through acetylation. HeLa cells were transfected transiently
with p(371)SRIF-CAT (1 Wg) and pRc/RSV-CREB341 (1 Wg).
pRc/RSV-PKA (0.5 Wg), and pCMV-p300 (2 Wg), either wild
type (WT) or mutant (HAT3 or 1-1737), were co-transfected
into cells as indicated. After transfection, cells were treated with
TSA (400 nM) for 24 h as indicated. The upper panel shows
CAT activity normalized against co-transfected L-galactosidase
activity. Error bars represent standard deviation (n = 3). The
lower panels are Western analysis using either anti-p300 or
anti-CREB antibodies.
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explanation for this di¡erence could be that the im-
portant role of the cAMP-induced CRE transcription
in physiological control plus high demand for p300
and CBP in many biological events dictate the par-
ticipation by both p300 and CBP in this CREB-
mediated transcription pathway.
Although the CRE transcription pathway is one of
the most intensively studied transcription events, the
precise roles that both CBP and p300 play in the
pathway are still unclear. The ability of CBP and
p300 to interact with basal transcription factors
and communicate with RNA polymerase II through
RNA helicase A [10^12] suggests the possibility that
these transcription coactivators may function as
adaptor proteins. This idea has been challenged by
the observation that stimulation of p300-induced es-
trogen receptor-mediated transcription required
chromatin [22]. This observation is supported by
the facts that p300 and CBP are HAT enzymes
[13,14]. The involvement of p300 HAT function in
transcription activation was observed further using
the point mutant lacking HAT activity in di¡erent
systems [23,28]. It has been reported that CBP/p300
coactivates transcription in both HAT-dependent
and HAT-independent ways [23]. Our data using
the CREB-participated transcription system support
this ¢nding and further indicate that p300 HAT
function has a major contribution to this transcrip-
tion process.
Our data showing p300 targeting for acetylation of
nucleosomes on activator-bound nucleosomal tem-
plates during the derepression of CREB-mediated
transcription on chromatin are consistent with pre-
vious detailed studies using yeast HAT complexes
[24,43]. Recently, a similar study, using a similar
chromatin transcription system, reported that p300-
dependent transcription was enhanced by acetyl CoA
and repressed by a p300 HAT-speci¢c inhibitor [44].
The required p300 HAT function involves p300 tar-
geting by Gal4-VP16 for histone acetylation prior to
transcription. These observations are consistent with
our study in that p300 targeting by Gal-CREB for
acetylation of nucleosomes was involved in CREB-
mediated transcription. They also showed that acti-
vators recruited p300 to chromatin templates by di-
rect interactions, but not through the HAT domain
of p300. Our study further showed that the recruit-
ment of p300 through the speci¢c interaction be-
tween the P-KID domain of CREB and the CREB-
binding domain of p300 was required for the tar-
geted acetylation of nucleosomes and the transcrip-
tion derepression on chromatin.
In summary, p300 recruited on chromatin by
PKA-phosphorylated CREB targets for acetylation
of nucleosomes at the promoter, and this targeting
acetylation is involved in derepression of the CREB-
mediated transcription. This acetylation function of
p300 plays a major role in CREB-mediated tran-
scription activation in vivo. Further studies using
puri¢ed basal transcription factors in reconstituted
transcription assays, and investigating structural
changes in chromatin after acetylation by p300/
CBP and involvement of chromatin remodeling in
p300-participated transcription derepression, will ex-
tend our understanding about the detailed mecha-
nisms the coactivator can use in the regulation of
transcription.
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